Ovid Therapeutics Inc. 8-K

What Happened Ovid Therapeutics (filed an 8‑K on July 8, 2026) reported that Jeffrey Rona transitioned from his roles as Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary effective July 6, 2026. The Board appointed Charles Carter (age 59), previously Senior Vice President of Finance and Financial Planning, as the Company’s Chief Financial Officer, principal financial officer, principal accounting officer and secretary effective the same date. The filing states Mr. Rona’s departure was not due to any disagreement regarding accounting, financial statements, internal controls, operations, policies or practices.

In connection with the separation, Ovid entered a Separation Agreement with Mr. Rona providing certain cash and benefit payments and post‑termination covenants, and a Consulting Agreement under which Mr. Rona will provide advisory services through December 31, 2027 (equity awards will continue to vest during the consulting period). The Company expects to file the full Separation Agreement and Consulting Agreement with its Form 10‑Q for the quarter ending September 30, 2026.

Key Details

• Effective date of change: July 6, 2026; Form 8‑K filed July 8, 2026.
• New CFO Charles Carter compensation: $460,000 annual base salary; annual cash bonus target = 35% of base salary.
• Equity grant to Mr. Carter: 50,000 restricted stock units, vesting in two equal annual installments beginning July 6, 2027; eligible for an additional $75,000 bonus tied to company and individual goals.
• Separation terms for Mr. Rona: 12 months of base salary paid monthly, prorated 2026 annual bonus (lump sum), up to 12 months COBRA, one‑year non‑solicit covenant; consulting retainer + hourly fees through Dec 31, 2027; outstanding equity continues vesting during consulting.

Why It Matters This 8‑K reports a change in senior financial leadership that could affect investor confidence in near‑term financial execution and reporting continuity. The company emphasizes there was no disagreement about accounting or controls, reducing immediate governance concern. Investors should note the near‑term cash costs from the separation and ongoing consulting arrangement and watch Ovid’s upcoming 10‑Q and future disclosures for the full agreements and any further detail on compensation expense or operational impacts.